LU91346I2 - Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige) - Google Patents

Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)

Info

Publication number
LU91346I2
LU91346I2 LU91346C LU91346C LU91346I2 LU 91346 I2 LU91346 I2 LU 91346I2 LU 91346 C LU91346 C LU 91346C LU 91346 C LU91346 C LU 91346C LU 91346 I2 LU91346 I2 LU 91346I2
Authority
LU
Luxembourg
Prior art keywords
prexige
lumiracoxib
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91346C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91346(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91346I2 publication Critical patent/LU91346I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91346C 1997-08-28 2007-07-11 Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige) LU91346I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5780397P 1997-08-28 1997-08-28
US6983797P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (fr) 1997-08-28 1998-08-26 Certains acides 5-alkyl-2-arylaminophenylacetiques et leurs derives

Publications (1)

Publication Number Publication Date
LU91346I2 true LU91346I2 (fr) 2007-09-11

Family

ID=26736901

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91346C LU91346I2 (fr) 1997-08-28 2007-07-11 Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91540C LU91540I2 (fr) 1997-08-28 2009-03-11 Robenacoxib-Onsior ou un de ses sels ou prémédicament vétérinairement acceptable

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91540C LU91540I2 (fr) 1997-08-28 2009-03-11 Robenacoxib-Onsior ou un de ses sels ou prémédicament vétérinairement acceptable

Country Status (35)

Country Link
US (5) US6291523B1 (fr)
EP (1) EP1007505B1 (fr)
JP (1) JP3704470B2 (fr)
KR (1) KR100637296B1 (fr)
CN (1) CN1140500C (fr)
AR (1) AR015157A1 (fr)
AT (1) ATE237580T1 (fr)
AU (1) AU743371B2 (fr)
BR (1) BR9812010B1 (fr)
CA (1) CA2298033C (fr)
CO (1) CO4960662A1 (fr)
CY (1) CY2007020I1 (fr)
CZ (1) CZ298522B6 (fr)
DE (4) DE122007000035I1 (fr)
DK (1) DK1007505T3 (fr)
ES (1) ES2197508T3 (fr)
FR (1) FR09C0011I2 (fr)
HK (1) HK1031374A1 (fr)
HU (1) HU225774B1 (fr)
ID (1) ID23953A (fr)
IL (2) IL134498A0 (fr)
LU (2) LU91346I2 (fr)
MY (1) MY127881A (fr)
NL (1) NL300379I2 (fr)
NO (2) NO326196B1 (fr)
NZ (1) NZ502669A (fr)
PE (1) PE108099A1 (fr)
PL (1) PL194480B1 (fr)
PT (1) PT1007505E (fr)
RU (1) RU2186762C2 (fr)
SI (1) SI1007505T1 (fr)
SK (1) SK283773B6 (fr)
TR (1) TR200000447T2 (fr)
TW (1) TWI250142B (fr)
WO (1) WO1999011605A1 (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1126841B1 (fr) * 1998-11-02 2004-12-15 Merck & Co., Inc. Combinaisons d'une agoniste 5ht1b/1d et d'un inhibiteur selective de cox-2 destinees au traitement de migraine
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
WO2002040018A1 (fr) * 2000-11-14 2002-05-23 Alcon, Inc. Traitement du glaucome et de l'hypertension oculaire
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CA2459879A1 (fr) 2001-09-10 2003-03-20 Sugen, Inc. Derives de 3-(4,5,6,7-tetrahydroindol-2-ylmethylidene)-2-indolinone comme inhibiteurs de kinases
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
EP1434576A4 (fr) 2001-09-13 2006-03-29 Kenneth E Miller Methode pour soulager la douleur
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
IL160970A0 (en) * 2001-11-06 2004-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
CA2492989C (fr) 2002-07-23 2012-11-20 Novartis Ag Composition d'onguent ophtalmique comprenant un medicament, une base d'onguent et un agent de solubilisation/dispersion
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004028448A2 (fr) * 2002-09-13 2004-04-08 Miller Kenneth E Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1575581A1 (fr) * 2002-12-18 2005-09-21 Novartis AG Combinaisons de valsartan avec des inhibiteurs de cox-2
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
WO2004093816A2 (fr) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de cyclo-oxygenase-2 et un agent modulateur de calcium pour le traitement de dommages au systeme nerveux central
WO2004093813A2 (fr) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
CA2519189C (fr) 2003-05-07 2012-07-17 Osteologix A/S Sels de strontium solubles dans l'eau pour le traitement de maladies des cartilages et/ou des os
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004103286A2 (fr) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions comprenant un inhibiteur selectif de la cyclooxygenase-2 et un agent cholinergique pour le traitement des reductions du debit sanguin ou des traumatismes affectant le systeme nerveux central
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
WO2005007106A2 (fr) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de la cyclooxygenase 2 et un modulateur du glutamate non-nmda pour le traitement d'une lesion du systeme nerveux central
WO2005009342A2 (fr) * 2003-07-16 2005-02-03 Pharmacia Corporation Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci
WO2005009354A2 (fr) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions contenant un inhibiteur selectif de la cyclooxygenase-2 et un inhibiteur des ikk, utilisees dans le traitement des troubles ou lesions d'origine ischemique du systeme nerveux central
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US20050130971A1 (en) * 2003-08-22 2005-06-16 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
WO2005023189A2 (fr) * 2003-09-03 2005-03-17 Pharmacia Corporation Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
EP1670417A2 (fr) * 2003-10-03 2006-06-21 Pharmacia Corporation Compositions a base d'inhibiteur selectif de la cyclooxygenase-2 administrees dans des conditions d'hypothermie pour le traitement de lesions ou de troubles du systeme nerveux central induits par une ischemie
CA2541265A1 (fr) * 2003-10-08 2005-04-28 Novartis Ag Compositions pharmaceutiques contenant un acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique
BRPI0415939A (pt) * 2003-11-12 2007-01-02 Pharmacia & Upjohn Co Llc composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
RU2390529C2 (ru) 2004-01-07 2010-05-27 Сейкагаку Корпорейшн Производное гиалуроновой кислоты и содержащее его лекарственное средство
KR20120091378A (ko) 2004-03-23 2012-08-17 노파르티스 아게 제약 조성물
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
ES2321535T3 (es) 2004-12-23 2009-06-08 Glaxo Group Limited Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandinas.
EP1912654A4 (fr) * 2005-02-22 2008-09-17 Merial Ltd Methodes de traitement selectif de troubles induits par cox-2 par administration de gamma-tocopherol
EP1877444A2 (fr) 2005-04-26 2008-01-16 Pfizer, Inc. Anticorps de la p-cadherine
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
EA201300320A1 (ru) 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203411B1 (fr) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. Dérivés de l'acide n-phénylanthranilique et leurs utilisations
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2268611A2 (fr) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Antagonistes d aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2010003120A2 (fr) 2008-07-03 2010-01-07 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (fr) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2011012622A1 (fr) 2009-07-30 2011-02-03 Glaxo Group Limited Dérivés de benzoxazinone pour traiter des troubles induits par glytl
WO2011014587A2 (fr) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
WO2011023753A1 (fr) 2009-08-27 2011-03-03 Glaxo Group Limited Dérivés de benzoxazine inhibiteurs du transport de glycine
SG182398A1 (en) 2010-01-06 2012-08-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
EP2665729B1 (fr) 2011-01-19 2015-04-01 Convergence Pharmaceuticals Limited Dérivés de pipérazine en tant que bloqueurs de canaux calciques cav2.2
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
PE20142083A1 (es) 2011-09-16 2014-12-30 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
TWI662971B (zh) 2017-03-14 2019-06-21 日商生化學工業股份有限公司 關節疾患處置用組成物及含有該組成物的套組
WO2018168921A1 (fr) 2017-03-14 2018-09-20 生化学工業株式会社 Composition pour traitement des maladies articulaires, et kit contenant cette composition
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
EA202190330A1 (ru) 2018-07-27 2021-06-04 КРКА, д.д., НОВО МЕСТО Способ получения полиморфной формы робенакоксиба
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
WO2023181053A1 (fr) 2022-03-23 2023-09-28 Alivira Animal Health Limited Procédé amélioré de purification de robénacoxib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES8404783A1 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
WO1996000716A1 (fr) 1994-06-29 1996-01-11 Ciba-Geigy Ag Nouveaux sels d'acide 2-[(2,6-dichlorophenyl) amine] phenylacetoxyacetique a cations basiques organiques
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
RU2186762C2 (ru) 2002-08-10
CA2298033C (fr) 2007-10-02
PT1007505E (pt) 2003-08-29
US6310099B1 (en) 2001-10-30
NO20000943L (no) 2000-02-25
WO1999011605A8 (fr) 2000-03-02
TWI250142B (en) 2006-03-01
AR015157A1 (es) 2001-04-18
BR9812010A (pt) 2000-12-12
DE69813570D1 (de) 2003-05-22
US6451858B2 (en) 2002-09-17
SK2472000A3 (en) 2000-09-12
HU225774B1 (en) 2007-08-28
FR09C0011I1 (fr) 2009-04-17
JP2001514244A (ja) 2001-09-11
CN1268112A (zh) 2000-09-27
LU91540I2 (fr) 2009-05-11
DE122009000013I1 (de) 2009-06-25
US20040122254A1 (en) 2004-06-24
ES2197508T3 (es) 2004-01-01
WO1999011605A1 (fr) 1999-03-11
NO20000943D0 (no) 2000-02-25
KR20010023344A (ko) 2001-03-26
US6291523B1 (en) 2001-09-18
US20020013369A1 (en) 2002-01-31
CY2007020I2 (el) 2012-01-25
ATE237580T1 (de) 2003-05-15
PL194480B1 (pl) 2007-06-29
HUP0002514A2 (hu) 2000-12-28
NL300379I1 (nl) 2009-05-06
HK1031374A1 (en) 2001-06-15
NO2009007I2 (no) 2010-06-07
JP3704470B2 (ja) 2005-10-12
DE122007000035I2 (de) 2010-07-01
CO4960662A1 (es) 2000-09-25
AU743371B2 (en) 2002-01-24
TR200000447T2 (tr) 2000-07-21
KR100637296B1 (ko) 2006-10-23
PL338357A1 (en) 2000-10-23
CY2007020I1 (el) 2012-01-25
IL134498A0 (en) 2001-04-30
SI1007505T1 (en) 2003-10-31
NL300379I2 (nl) 2010-02-01
AU9534098A (en) 1999-03-22
HUP0002514A3 (en) 2002-11-28
DE69813570T2 (de) 2004-02-12
EP1007505B1 (fr) 2003-04-16
CZ298522B6 (cs) 2007-10-24
CN1140500C (zh) 2004-03-03
FR09C0011I2 (fr) 2011-04-01
EP1007505A1 (fr) 2000-06-14
IL134498A (en) 2009-06-15
NO2009007I1 (no) 2009-04-06
ID23953A (id) 2000-06-08
NZ502669A (en) 2002-02-01
SK283773B6 (sk) 2004-01-08
DK1007505T3 (da) 2003-07-21
NO326196B1 (no) 2008-10-13
US20020183391A1 (en) 2002-12-05
CZ2000714A3 (cs) 2000-06-14
BR9812010B1 (pt) 2010-12-14
CA2298033A1 (fr) 1999-03-11
US7115662B2 (en) 2006-10-03
PE108099A1 (es) 1999-11-18
MY127881A (en) 2006-12-29
US6727281B2 (en) 2004-04-27
DE122007000035I1 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU91673I2 (fr) &#34;Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)&#34;
LU91138I2 (fr) Glulisine d&#39;insuline et ses dérivés pharmaceutiquement acceptables.
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91452I2 (fr) &#34;Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)&#34;
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
NO983169L (no) Hetrosykel-kondenserte morfinoidderivater (31)
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
PL337773A1 (en) Derivatives of benzimidazoles
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
IL131201A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
NO20000231D0 (no) Dolastatin-15-derivater
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi